Postmenopausal Osteoporosis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.90 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Postmenopausal Osteoporosis Market Analysis
The postmenopausal osteoporosis market is projected to register a CAGR of 3.9% during the forecast period of 2022-2027.
The outbreak of Covid-19 has significantly impacted the healthcare industry, including relative negligence of chronic diseases such as osteoporosis. A survey conducted by the National Osteoporosis Foundation and International Osteoporosis Foundation concluded that the major impact includes delays in scanning for diagnosis, interruptions in the supply of drugs and raw material, an increase in telemedicine consultations, and a decrease in parenteral medicine delivery. Further, according to a research study published in March 2021, titled 'Effects of COVID-19 Lockdown on Adherence to Individual Home- or Gym-Based Exercise Training among Women with Postmenopausal Osteoporosis', being at home can result in decreased physical activity and sedentary behavior, the COVID-19 epidemic and its constraints may have interfered with the study participants' schedules and motivation, and the reduction or lack of social bonds that are usually essential to encourage the elderly to exercise may have reduced. Hence, COVID-19 is expected to have a significant impact on the postmenopausal osteoporosis market, however, with the decreasing COVID-19 cases and large-scale vaccination programs, the studied market is expected to regain its full potential over the forecast period.
The aging population and lifestyle changes are the key factors responsible for the growth of the postmenopausal osteoporosis market as the older population is more prone to osteoporosis and thus increase in their population is expected to be a significant growth factor. For instance, according to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. Hence, the market is projected to grow during the forecast period with an increase in demand for therapy of postmenopausal osteoporosis in the older population.
Additionally, lifestyle changes such as lack of exercise, high consumption of alcohol or smoking, prolonged work duration, and unhealthy eating habits also impact the menopausal period and lead to osteoporosis in many women worldwide. Age, smoking, alcohol, and consumption of medications used to treat various diseases such as gonadotropins, excess consumption of thyroid hormone, and cytotoxic agents are some of the risk factors for causing low bone density and thereby developing osteoporosis after menopause in women. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture. Therefore, due to the aforementioned factors, the studied market is expected to grow over the forecast period. However, low awareness about postmenopausal osteoporosis is expected to restrain the growth of the studied market during the forecast period.
Postmenopausal Osteoporosis Market Trends
This section covers the major market trends shaping the Postmenopausal Osteoporosis Market according to our research experts:
The Bisphosphonates Segment is Expected to Hold Largest Share in the Postmenopausal Osteoporosis Market Over Forecast Period
The bisphosphonates class of drug is expected to be accounted for the market's maximum share, which can be attributed to their ability to prevent the loss of bone density and thereby minimize the fracture risk by 50%. Additionally, bisphosphonates can be tolerated by most patients on a long-term basis. For instance, according to an article published in April 2021, titled 'Bisphosphonate Medications for Osteoporosis: Concerns Regarding Risks and Side Effects', by inhibiting osteoclast activity, bisphosphonates reduce bone resorption and numerous studies have demonstrated that this family of drugs can increase bone density and lower fracture risk in those with low bone density. Hence, they are prescribed widely for most patients with osteoporosis and thus expected to have a significant share in the studied market.
Alendronate, risedronate, ibandronate, and zoledronic acid are some of the most prescribed bisphosphonates to prevent and treat postmenopausal osteoporosis. A new regimen through the intravenous route is under investigation, and positive results from the trial can further accelerate the market of bisphosphonates during the forecast period. Bisphosphonates are generally prescribed for five years, and the bone-protective benefit of the drug continues even after the treatment discontinuation. Therefore, owing to the above-mentioned factors, the bisphosphate segment is expected to have a significant market share in the postmenopausal osteoporosis market.
North America Region is Expected to Occupy a Significant Share in the Postmenopausal Osteoporosis Market
North America contributes the highest revenue in the market due to its developed healthcare infrastructure, presence of major industry players, high diagnosis and treatment rate, more patient compliance, and large patient base. The United States contributes the maximum share in North America. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 18.8% of women aged 50 years or more had osteoporosis. The prevalence is expected to increase further due to sedentary lifestyles and unhealthy eating & drinking habits. According to the National Osteoporosis Foundation, it is projected that by 2030, about 71 million Americans will have osteoporosis and low bone mass condition.
High research and development activities due to investment by market players and research institutes are expected to further accelerate the market growth during the forecast period from 2022 to 2027. According to data published on clinicaltrial.gov as of June 2021, about 25 active Phase III and Phase IV clinical trials are going on in the United States for osteoporosis drugs. Also, as per the May 2022 update of the National Institute of Health of the United States, about USD 155 million in funding is allocated for osteoporosis in 2021, an increase of USD 7 million from the previous years, and this funding are further expected to have a positive impact on the studied market. Therefore, due to the above-mentioned factors, the postmenopausal osteoporosis market is expected to grow in the North American region over the forecast period.
Postmenopausal Osteoporosis Industry Overview
The postmenopausal osteoporosis market is fragmented and competitive due to several generics in the market. However, some of the key players operating in the market are Novartis International AG, Eli Lilly and CO., Pfizer Inc., Merck & Co., Inc., BiologicsMD, AbbVie (Allergan plc.), and Cipla Inc. Increasing awareness about postmenopausal osteoporosis, developing new drugs, and partnerships or collaborations to reach their drugs at maximum patients are some strategies market players are utilizing to gain market share in the industry.
Postmenopausal Osteoporosis Market Leaders
-
Amgen Inc.
-
Eli Lilly and Co.
-
F. Hoffmann-La Roche Ltd
-
Merck & Co., Inc.
-
Allergan plc
*Disclaimer: Major Players sorted in no particular order
Postmenopausal Osteoporosis Market News
- In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Edirol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai.
- In January 2021, the Asia Pacific Consortium on Osteoporosis (APCO) launched pan-Asia Pacific clinical practice standards to screen, diagnose, and manage osteoporosis that will majorly target a broad range of high-risk groups. The program is expected to increase further awareness in the region, which is expected to boost the market in Asia-Pacific.
Postmenopausal Osteoporosis Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase in Geriatric Population
- 4.2.2 Investment by Market Players and Thereby Strong Pipeline
-
4.3 Market Restraints
- 4.3.1 Low Awarenss about Postmenopause Osteoporosis
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Treatment
- 5.1.1 Vitamin D
- 5.1.2 Bisphosphonates
- 5.1.3 Hormone Replacement Therapy
- 5.1.4 Parathyroid Hormone Therapy
- 5.1.5 Others
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Online Pharmacies
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amgen Inc.
- 6.1.2 Eli Lilly and CO.
- 6.1.3 Pfizer Inc.
- 6.1.4 Proctor & Gamble Co.
- 6.1.5 Novartis International AG
- 6.1.6 Clonz Biotech
- 6.1.7 Ligand Pharmaceuticals Incorporated.
- 6.1.8 Merck & Co., Inc
- 6.1.9 BiologicsMD
- 6.1.10 Enteris BioPharma
- 6.1.11 Oncobiologics, Inc.
- 6.1.12 AbbVie (Allergan plc)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPostmenopausal Osteoporosis Industry Segmentation
As per the scope of the report, when women go through a transitional menopausal period, more bone resorption happen than formation due to a drop in estrogen level, resulting in osteoporosis. Therapy or treatment for this condition is considered in the report's scope. The postmenopausal osteoporosis market is segmented by treatment (vitamin D, bisphosphonates, hormone replacement therapy, parathyroid hormone therapy, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment | Vitamin D | |
| Bisphosphonates | ||
| Hormone Replacement Therapy | ||
| Parathyroid Hormone Therapy | ||
| Others | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Postmenopausal Osteoporosis Market Research FAQs
What is the current Global Postmenopausal Osteoporosis Market size?
The Global Postmenopausal Osteoporosis Market is projected to register a CAGR of 3.9% during the forecast period (2024-2029)
Who are the key players in Global Postmenopausal Osteoporosis Market?
Amgen Inc. , Eli Lilly and Co. , F. Hoffmann-La Roche Ltd , Merck & Co., Inc. and Allergan plc are the major companies operating in the Global Postmenopausal Osteoporosis Market.
Which is the fastest growing region in Global Postmenopausal Osteoporosis Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Postmenopausal Osteoporosis Market?
In 2024, the North America accounts for the largest market share in Global Postmenopausal Osteoporosis Market.
What years does this Global Postmenopausal Osteoporosis Market cover?
The report covers the Global Postmenopausal Osteoporosis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Postmenopausal Osteoporosis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Postmenopausal Osteoporosis Industry Report
Statistics for the 2024 Global Postmenopausal Osteoporosis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Postmenopausal Osteoporosis analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
